TetraGraph connects surgical data to the cloud
TetraConnect is the first cloud-based engine supporting anesthesiologists in monitoring patients’ neuromuscular blockade during and after surgery. Data from the TetraGraph monitoring system can be viewed on a tablet, smartphone or PC or exported into standard industry formats. The tool is also ideal to facilitate clinical research of patients undergoing anesthesia.
”Senzime is leading the digital transformation of neuromuscular monitoring in the operating room. With the launch of TetraConnect clinicians around the world can now share patient data and analyze trends in seconds. This is yet another step towards our mission to develop high-technology digital solutions to help save lives, enable precision-based medicine, reduce complications and reduce health care costs for surgical procedures”, says Pia Renaudin, CEO Senzime.
TetraConnect will be sold as a stand-alone software and available in all markets where the TetraGraph is marketed.
6 out of 10 patients experience Residual Neuromuscular Blockade at the time of extubation. Monitoring the effects of neuromuscular blocking drugs ensures their appropriate intra-operative use and helps prevent residual neuromuscular weakness.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: email@example.com
TO THE EDITORS
Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com